A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

NCT02425891 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

902

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody
DRUG: Nab-Paclitaxel
DRUG: Placebo

Sponsor

Hoffmann-La Roche